Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study

Fig. 1

Study population. Eligible patients were classified into four groups: low-risk initial treatment-responsive group (n = 116), low-risk initial treatment-resistant group (n = 28), high-risk initial treatment-responsive group (n = 27), and high-risk initial treatment-resistant group (n = 10)

Back to article page